FMI Foundation Medicine Inc.

Foundation Medicine Announces Timing for First Quarter 2018 Financial Results and Conference Call

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that financial results for the company's first quarter ended March 31, 2018 will be released on Wednesday, May 2, 2018. The management team will host a conference call on Wednesday, May 2, 2018, at 4:30 p.m. ET to discuss the company's financial results and recent developments. The call can be accessed by dialing 1-844-784-1732 (domestic) or 1-412-902-6714 (international) five minutes prior to the start of the call. A passcode is not required to access the live call from either number. A replay of the conference call will be available until May 16, 2018 and can be accessed by dialing 1-412-317-0088 and providing the passcode 10119532.

The live, listen-only webcast of the conference call may be accessed by visiting the investors’ section of the company's website at investors.foundationmedicine.com. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company's website for two weeks following the call.

About Foundation Medicine

Foundation Medicine (NASDAQ:FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit http://www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).

Foundation Medicine® is a registered trademark of Foundation Medicine, Inc.

EN
17/04/2018

Underlying

FMIFoundation Medicine Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Foundation Medicine Inc.

Free Trial
FMI Foundation Medi...

1 director sold

A director at Foundation Medicine Inc sold 73,173 shares at 137.000USD and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...

FMI FOUNDATION MEDICINE INC.
08/03/18 August 3, 2018 1 EN
 PRESS RELEASE
Free
FMI Foundation Medi...

Foundation Medicine Announces 2018 First Quarter Results and Recent Hi...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine (NASDAQ:FMI) today reported financial and operational results for the first quarter ended March 31, 2018. Highlights for the quarter included: Posted revenue of $52.8 million, 101% year-over-year growth; Reported 21,861 clinical tests, 57% year-over-year growth; Achieved broad Medicare coverage through a final National Coverage Determination (NCD) from the Centers for Medicare and Medicaid Services (CMS) for FoundationOne...

May 2, 2018 1 EN
 PRESS RELEASE
Free
FMI Foundation Medi...

Foundation Medicine Launches Gene Expression Profiling Program to Iden...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc. (NASDAQ:FMI) today announced a comprehensive gene expression profiling (GEP) program to support precision oncology clinical research and development. This initiative, which provides a natural complement to Foundation Medicine’s comprehensive genomic profiling (CGP) suite of molecular information tests, further enhances support for the Company’s biopharma partners in the efficient identification of known and novel genomic and expression-based biomarkers of response fo...

May 2, 2018 1 EN
 PRESS RELEASE
Free
FMI Foundation Medi...

Foundation Medicine, Roche and DIAN Diagnostics Collaborate to Advance...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc., (NASDAQ:FMI), F. Hoffmann-La Roche Ltd (Roche) and DIAN Diagnostics Group, Co., Ltd. (DIAN), today announced a three-party collaboration to integrate Foundation Medicine’s comprehensive genomic profiling (CGP) assays into clinical patient care in mainland China. Under the collaboration: DIAN, a leader in the development and supply of Chinese medical diagnostic products and services, becomes the exclusive clinical sequencing partner in China for...

April 26, 2018 1 EN
 PRESS RELEASE
Free
FMI Foundation Medi...

Foundation Medicine’s New Liquid Biopsy Assay Granted Breakthrough D...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the U.S. Food and Drug Administration (FDA) granted a Breakthrough Device designation (formerly Expedited Access Pathway program) for its new liquid biopsy assay, which is an expanded version of its FoundationACT® assay. The new assay will include more than 70 genes and genomic biomarkers for microsatellite instability (MSI) and blood tumor mutational burden (bTMB). If approved, this test could be the first FDA-approved liquid biopsy...

April 26, 2018 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch